Shandong Weigao Group Medical Polymer Company Limited (“Weigao Group”) disclosed a next-day return confirming the on-market repurchase of 0.22 million H-shares on 18 September 2026. The transaction was executed on the Hong Kong Stock Exchange at prices ranging between HKD 3.115 and HKD 3.15 per share, with a volume-weighted average price of HKD 3.13, for a total outlay of HKD 0.69 million.

Following the buyback, Weigao Group’s issued share capital (excluding treasury shares) declined to 4.46 billion shares, representing a 0.0049% reduction from the preceding day. Concurrently, the company’s treasury-share balance increased to 65.67 million shares, equal to roughly 1.45% of total issued shares.

The repurchase formed part of the mandate approved at the annual general meeting on 29 May 2026, which authorises the company to buy back up to 446.46 million shares. Including the latest transaction, Weigao Group has repurchased an aggregate 8.34 million shares under this mandate, equivalent to 1.87% of the issued share base on the mandate date. In line with Hong Kong listing rules, the company is subject to a moratorium on new share issues or the sale of treasury shares until 19 October 2026.

The board confirmed that all repurchase activities complied with relevant listing rules, regulatory requirements and the company’s internal authorisations.